treatment
measl
pneumon
immunocompromis
adult
establish
describ
patient
hodgkin
lymphoma
develop
acut
pneumonia
measl
infect
day
intraven
ribavirin
immunoglobulin
administr
day
patient
develop
acut
respiratori
failur
examin
transbronchi
pulmonari
biopsi
show
warthinfinkeldey
giant
cell
pathognomon
measl
pneumon
patient
die
despit
aggress
support
care
case
review
literatur
show
measl
pneumon
routin
fatal
patient
cancer
suggest
antivir
drug
consid
soon
diagnosi
establish
background
treatment
measl
pneumon
immunocompromis
adult
establish
describ
patient
hodgkin
lymphoma
develop
acut
pneumonia
measl
infect
day
intraven
ribavirin
immunoglobulin
administr
day
patient
develop
acut
respiratori
failur
examin
transbronchi
pulmonari
biopsi
show
warthinfinkeldey
giant
cell
pathognomon
measl
pneumon
patient
die
despit
aggress
support
care
case
review
literatur
show
measl
pneumon
routin
fatal
patient
cancer
suggest
antivir
drug
consid
soon
diagnosi
establish
case
measl
report
europ
epidem
still
ongo
case
report
european
center
diseas
control
prevent
ecdc
franc
itali
romania
spain
uk
account
case
outbreak
report
sweden
denmark
germani
itali
uk
england
wale
lithuania
netherland
franc
case
occur
children
young
adult
overal
patient
hospitalis
includ
sever
pneumonia
encephalitismyel
patient
die
adult
cancer
measl
frequent
atyp
lead
progress
giant
cell
pneumonia
enceph
death
two
fatal
case
measl
pneumon
report
adult
cancer
none
receiv
antivir
drug
report
case
measl
pneumon
patient
hodgkin
lymphoma
receiv
ribavirin
well
immunoglobulin
young
man
earli
admit
hospit
suspect
measl
histori
measl
vaccin
three
month
earlier
diagnos
stage
iv
hodgkin
lymphoma
mediastin
lymph
node
pulmonari
excav
left
apic
lobe
cultur
respiratori
sampl
neg
bacteria
mycobacteria
fungi
respiratori
virus
detect
influenza
viru
parainfluenza
viru
metapneumoviru
rhinoviru
coronaviru
adenoviru
complet
first
beacopp
escal
bleomycin
etoposid
doxorubicin
cyclophosphamid
vincristin
procarbazin
prednison
chemotherapi
cycl
patient
discharg
home
two
day
start
second
cycl
chemotherapi
patient
experienc
fever
sore
throat
conjunct
day
characterist
ill
figur
erythemat
rash
rapidli
spread
face
trunk
koplik
spot
observ
diagnosi
measl
consid
patient
refer
infecti
diseas
unit
serolog
studi
neg
igg
igm
antibodi
measl
measl
viru
mv
detect
nasal
swab
real
time
revers
transcriptas
rt
pcr
sequenc
basepair
nucleocapsid
gene
strain
indistinguish
genotyp
circul
franc
day
febril
neutropenia
occur
nadir
piperacillintazobactam
start
day
neutrophil
cell
count
increas
patient
experienc
progress
short
breath
chestct
scan
visualis
bilater
interstiti
infiltr
day
fibreopt
bronchoscopi
show
bronchial
inflamm
microscop
examin
bronchoalveolar
lavag
bal
fluid
show
leucocyt
worsen
respiratori
failur
patient
ventil
prone
posit
receiv
inhal
nitric
oxid
final
requir
venoven
extracorpor
membran
oxygen
ecmo
day
ribavirin
stop
day
therapi
lack
efficaci
cours
diseas
occurr
haemolyt
anaemia
day
ventilatedassoci
pneumonia
suspect
cultur
bal
grew
p
aeruginosa
mv
still
detect
pcr
amplif
ceftazidim
amikacin
start
day
patient
die
unexplain
refractori
hypotens
associ
renal
failur
sever
metabol
acidosi
attribut
propofol
propofolrel
infus
syndrom
use
high
dose
sedat
ecmo
report
case
measl
pneumon
treatment
advancedstag
hodgkin
lymphoma
intraven
administr
ribavirin
immunoglobulin
day
onset
pneumon
prevent
subsequ
fatal
outcom
sever
immunocompromis
adult
five
case
measl
pneumon
report
includ
four
death
case
death
underli
diseas
advanc
hiv
infect
lymphoma
chemotherapyinduc
neutropenia
rhabdomyosarcoma
factor
predict
poor
outcom
examin
literatur
patient
follow
condit
may
predispos
fatal
outcom
hodgkin
lymphoma
unrespons
chemotherapi
profound
chemotherapyinduc
neutropenia
onset
rash
sustain
mvinduc
immun
suppress
respons
prolong
lymphocyt
deplet
day
worsen
patient
immun
statu
patient
unabl
mount
adequ
immun
respons
shown
neg
serolog
test
day
therefor
measl
diagnos
use
real
time
rtpcr
valid
detect
mv
clinic
specimen
patient
manag
shed
mv
lung
immunocompromis
patient
yet
report
although
rtpcr
design
diagnosi
quantifi
viral
load
result
analys
suggest
treatment
lack
efficaci
inde
viral
shed
last
week
signific
concentr
despit
aggress
treatment
figur
clinic
event
evolut
biolog
marker
treatment
given
patient
measl
advanc
hodgkin
lymphoma
horizont
line
show
absolut
neutrophil
count
cellsml
major
risk
factor
invas
aspergillosi
bal
bronchoalveolar
lavag
patient
receiv
ribavirin
well
intraven
immunoglobulin
none
two
previous
report
patient
malign
diseas
receiv
antivir
drug
patient
nonhodgkin
lymphoma
patient
rhabdomyosarcoma
die
pneumonia
convers
three
hivinfect
patient
treat
ribavirin
andor
immunoglobulin
one
patient
treat
ribavirin
respiratori
deterior
immunoglobulin
endotrach
intub
surviv
dissemin
measl
two
receiv
ribavirin
mechan
ventil
fatal
outcom
case
suggest
ribavirin
immunoglobulin
consid
use
patient
sever
impair
cellular
immun
soon
diagnosi
measl
establish
vaccin
best
way
prevent
measl
liveattenu
viru
vaccin
contraind
immunocompromis
patient
malign
tumour
receiv
immunosuppress
therapi
immun
measl
probabl
check
patient
immun
defici
context
epidem
without
circul
neutralis
antibodi
advis
seek
prompt
medic
attent
suspect
evid
exposur
measl
receiv
postexposur
prophylact
intraven
immunoglobulin
although
treatment
effici
measl
pneumon
sever
immunocompromis
patient
establish
high
likelihood
fatal
outcom
may
justifi
earli
treatment
measl
pneumon
frequent
fatal
immunocompromis
host
given
mostli
fatal
outcom
measl
occur
immun
compromis
patient
treatment
tri
soon
possibl
vaccin
administ
least
week
initi
immunosuppress
therapi
